A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment

Phase 3

Active, not recruiting

• Conditions: Blepharitis
• Interventions: Drug: Pimecrolimus 0.3% Ophthalmic Ointment; Drug: Placebo Ophthalmic Ointment

• Registration Number: NCT06400511
• Lead Sponsor: Famy Life Sciences, a Viatris Company

Brief Summary

The objective of this study is to determine the efficacy and safety of Pimecrolimus 0.3% (MR-139) Ophthalmic Ointment.

Detailed Description

The study is designed to evaluate Pimecrolimus 0.3% Ophthalmic Ointment in subjects with blepharitis to complete resolution (score = 0 on grading scale of 0-4) for eyelid debris after BID use at Week 6 in the Study Eye.

Study Timeline

• Study Start: 2024-04-22
• Study First Submitted: 2024-05-01
• Study First Submitted QC: 2024-05-01
• Study First Posted: 2024-05-06
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-01
• Last Update Posted: 2025-05-04
• Primary Completion: 2025-11
• Study Completion: 2025-12

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 477

Inclusion Criteria

1. Male or female subjects aged ≥ 2 years of age or older at Visit 1, with a diagnosis of blepharitis confirmed by the investigator.
2. Subjects under 18 must able to be examined at the slit lamp (handheld) without systemic anesthesia.
3. A self-reported history of at least 1 previous episode of blepharitis.
4. Adult subjects have provided verbal and written informed consent. For subjects under 16 years of age, a parent or legal guardian of each subject must provide written informed consent and sign the HIPAA form (or equivalent, if applicable), approved by the appropriate Institutional Review Board (IRB)/Ethical Committee (EC). Whenever practical and appropriate per local requirements, a child's assent should also be sought before inclusion into the study.
5. Subjects who have not responded adequately to lid hygiene in the past (self-reported).
6. Have a Corrected Distance Visual Acuity (CDVA) greater than or equal to 0.7 logMar in each eye, assessed with the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Subjects may be refracted if needed.
7. Subjects must be able to comply with the requirements of the protocol including the ability to self-administer or receive topical treatment twice a day to their eyelid margins.
8. Be literate and able to complete questionnaires independently, or in the case of pediatric patients, can comprehend the questionnaires with the help of a parent/guardian or interviewer.
9. Women of childbearing potential (WOCBP) must have a negative urine pregnancy test at Visit 1 and must be willing to use an adequate method of contraception throughout the study and 30 days from the last application of the study treatment.

Exclusion Criteria

1. Subjects who have received a COVID vaccination or recovered from COVID-19 symptoms less than 1 week prior to baseline visit.
2. Subjects with a history of, or active herpetic or neurotrophic keratitis.
3. Subjects who, in the opinion of the investigator, have abnormal eyelid anatomy (other than due to blepharitis) that might adversely affect clinical signs and symptoms, including but not limited to lagophthalmos, malposition of the eyelid or tumor(s) of the eyelid or eyelid margin.
4. Subjects who have received other treatments for blepharitis within 30 days of Visit 1.
5. Subjects with known hypersensitivity to study medications, or to any diagnostic agents to be used in the study.
6. Subjects who are currently enrolled in an investigational drug or device study or have used an investigational drug or device within the 30 days prior to the baseline visit and during the treatment period.
7. Subjects who, in the opinion of the investigator, would be unable to adhere to the study protocol.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Pimecrolimus 0.3% Ophthalmic Ointment	Pimecrolimus 0.3% Ophthalmic Ointment	Study Drug
Placebo Ophthalmic Ointment	Placebo Ophthalmic Ointment	Placebo

Primary Outcome Measures

Name	Time	Method
Efficacy of Study Drug	6 weeks	Complete Resolution (score =0 on grading scale 0-4) of eyelid debris. A higher score indicates a worse outcome.

Secondary Outcome Measures

Name	Time	Method
Ocular Discomfort Score	12 weeks	Change from baseline on ocular discomfort score visual analogue scale on a scale from 0-100 scale where 0 indicates no discomfort and 100 indicates maximum discomfort. A higher score indicates a worse outcome.
Eyelid Debris	12 weeks	Complete resolution (score-0 on grading scale of 0-4) for eyelid debris. A higher score indicates a worse outcome.
Eyelid Meibomian Gland Plugging	12 weeks	Complete resolution (score +0 on grading scale 0-4) and change from baseline for eyelid meibomian gland plugging. A higher score indicates a worse outcome.
Eyelid Meibum Character	6 weeks	Complete resolution and change from baseline for eyelid meibum character.
Adverse Events	12 Weeks	Incidence of Adverse Events

Trial Locations

Locations (3)

Clinical Investigative Site; 🇺🇸 Phoenix, Arizona, United States

Clinical Investigator Site; 🇺🇸 Lynchburg, Virginia, United States

Investigative Site; 🇺🇸 Saint Louis, Missouri, United States